Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050076 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.
A Phase 2 study of Congestive Heart Failure, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
- 20
- Study locations
NCT00050076: Completed Phase 2 study of Congestive Heart Failure, sponsored by Takeda.
NCT00050076 is a Phase 2 study of Congestive Heart Failure that has completed, run by Takeda. The registered enrollment target is 204 participants, below the 326-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050076, a Phase 2 study of Congestive Heart Failure, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effect of two different doses of MCC-135, once daily (QD) or twice daily (BID), on the disease state and the quality of life in subjects with congestive heart failure.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MCC-135
Study Locations (20)
California
- Capitol Intervention Cardiology - Carmichael
- San Diego Cardiovascular - Encinitas
- LAC & USC Medical Center - Los Angeles
- ARI Clinical Trials, Inc Arrhythmia Research & Cardiology Health Center - Redondo Beach
- Clinical Trials Research - Roseville
- Sacramento Heart & Vascular Medical Associates - Sacramento
- University of California San Diego - San Diego
- Apex Research Institute - Santa Ana
Florida
- Cardiology Consultants PA - Daytona Beach
- Cardiology Associates of Fort Lauderdale - Fort Lauderdale
- Jacksonville Center for Clinical Research - Jacksonville
- Cardiovascular Center of Sarasota - Sarasota
Arizona
- Maricopa Medical Center - Phoenix
- University of Arizona Medical Center - Tucson
Kentucky
- Medical Center Cardiologist - Louisville
- Louisville Cardiology Medical Group, PSC - Louisville
Louisiana
- Louisiana Heart Center - Chalmette
- New Orleans Center for Clinical Research - New Orleans
Georgia
- Southern Clinical Research & Management - Augusta
Indiana
- Medical Group of Fort Wayne, PC - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2002-08 |
| Est. Completion | 2003-08 |
| Phase | Phase 2 |
What the finished NCT00050076 record still lists
NCT00050076 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 326-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00050076 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00050076 about?
NCT00050076 is a clinical study titled "Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.". The purpose of this study is to determine the effect of two different doses of MCC-135, once daily (QD) or twice daily (BID), on the disease state and the quality of life in subjects with congestive heart failure.
What is the current status of trial NCT00050076?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2002-08. Estimated completion is 2003-08.
What conditions does trial NCT00050076 study?
This clinical trial studies the following conditions: Congestive Heart Failure.
What interventions are being tested in trial NCT00050076?
The interventions under investigation include: Placebo (DRUG), MCC-135 (DRUG).
Who is sponsoring clinical trial NCT00050076?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00050076 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congestive Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00050076's enrollment target sits among peer trials
204 20th of 51 higher than 32 of 51 other Congestive Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congestive Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
ACTIVE NOT RECRUITING · Phase 2
-
At-Home Automated External Defibrillator (AED) Training Study
COMPLETED · Phase 2
-
Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes
COMPLETED · Phase 2
-
Device Evaluation of Contak Renewal 2and Easytrak 2 - DECREASE-HF
COMPLETED · Phase 2
-
Palliative Care for People With HF
RECRUITING
-
Circulating Markers for Ischemic Heart Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia